Last reviewed · How we verify
UniCAR02-T-pPSMA
At a glance
| Generic name | UniCAR02-T-pPSMA |
|---|---|
| Sponsor | AvenCell Therapeutics, Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
- Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- UniCAR02-T-pPSMA CI brief — competitive landscape report
- UniCAR02-T-pPSMA updates RSS · CI watch RSS
- AvenCell Therapeutics, Inc. portfolio CI